CirCode Biomed received FDA clearance to begin a U.S. clinical trial of its circular RNA therapeutic, marking a first test of the circular RNA modality in the American regulatory environment. The startup plans an early‑phase study to evaluate safety and initial biological activity, positioning circular RNA as an alternative to linear mRNA approaches with potential stability and translational benefits. The clearance moves the field of RNA therapeutics beyond linear mRNA and opens U.S. patient access to a distinct platform that could influence future delivery and dosing strategies for genetic medicines. Source: Company disclosure reported by industry news outlets.